Claims for Patent: 10,468,123

Summary for Patent: 10,468,123

Title:	Self correction for spatial orientation and motion of portable clinical analyzers
Abstract:	The present invention covers the integration and utility of accelerometer features into a clinical analysis system. For example, measurement of dynamic acceleration and orientation of a blood-testing instrument with respect to Earth\'s gravitational field may be used to determine reliability of a test procedure and optionally to provide corrective elements thereof.
Inventor(s):	Vandersleen; Gary (Plainsboro, NJ), Emeric; Pierre (Princeton, NJ), Wasserman; Paul (Oakhurst, NJ), Soman; Narendra (Hillsborough, NJ), Davis; Graham (Princeton, NJ)
Assignee:	Abbott Point of Care Inc. (Princeton, NJ)
Application Number:	15/877,626
Patent Claims:	1. A method of in vitro analysis of a sample comprising blood cells, comprising: inserting a test device in a port of an analyzer comprising a computing device and at least one accelerometer; receiving the sample comprising the blood cells in a sample entry port of the test device; actuating a pump, thereby moving the received sample in the test device through a conduit over at least one sensor configured to generate an electric signal based on: (i) a concentration of a target analyte in the sample, or (ii) a property of the sample, upon the at least one sensor being contacted with the sample in the conduit during a test cycle of the test device; determining spatial orientation and motion of the analyzer during the test cycle of the test device by the computing device using data collected by the at least one accelerometer; comparing the determined spatial orientation to a threshold operating spatial plane for the test device; comparing the determined motion to a threshold rate of motion for the test device; and applying a correction factor to the electric signal generated by the at least one sensor, when at least one of: (i) the determined spatial orientation exceeds the threshold operating spatial plane, and (ii) the determined motion exceeds the threshold rate of motion, wherein the correction factor is at least one of a blood non-homogeneity correction factor, a blood cell sedimentation correction factor, and a blood motion factor; to produce a corrected signal. 2. The method of claim 1, wherein the blood cells from the sample at least partially sediment on the at least one sensor during the test cycle. 3. The method of claim 2, wherein a rate of cell sedimentation with respect to the at least one sensor is dependent on at least one of the spatial orientation and the motion of the analyzer during the test cycle. 4. The method of claim 1, wherein the at least one sensor is an electrochemical sensor. 5. The method of claim 1, wherein the at least one sensor responds to the target analyte or the property selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), beta human chorionic gonadotropin (bHCG), carbon dioxide partial pressure (pCO2), partial pressure oxygen (pO2), pH, prothrombin time (PT), activated clotting time (ACT), activated partial thromboplastin time (APTT), and prothrombin time international normalized ratio (PT INR), sodium, potassium, chloride, calcium, urea, glucose, creatinine, lactate, oxygen and carbon dioxide. 6. The method of claim 1, wherein the at least one sensor responds to the target analyte or the property selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), activated clotting time (ACT), activated partial thromboplastin time (APTT) and prothrombin time international normalized ratio (PT INR). 7. The method of claim 1, wherein the computing device is configured to measure dynamic acceleration and static acceleration to determine the motion and the spatial orientation of the analyzer, respectively. 8. The method of claim 7, wherein the computing device is configured to measure static acceleration on at least three axes of the analyzer to determine the spatial orientation of the analyzer, and the determining the spatial orientation comprises determining at least one of roll, pitch, and yaw of the analyzer based on the measured static acceleration on the at least three axes of the analyzer. 9. The method of claim 8, wherein: the comparing the determined spatial orientation to the threshold operating spatial plane comprises at least one of: comparing the determined roll of the analyzer to a threshold roll; comparing the determined pitch of the analyzer to a threshold pitch; and comparing the determined yaw of the analyzer to a threshold yaw; and applying the correction factor when the determined spatial orientation exceeds the threshold operating spatial plane comprises applying the correction factor when at least one of: (iii) the determined roll of the analyzer exceeds the threshold roll, (iv) the determined pitch of the analyzer exceeds the threshold pitch, and (v) the determined yaw of the analyzer exceeds the threshold yaw, wherein the correction factor is at least one of the blood non-homogeneity correction factor and the blood cell sedimentation correction factor. 10. The method of claim 1, further comprising: determining a stage of the test cycle by the analyzer; and determining by the computing device at least one of the threshold operating spatial plane and the threshold rate of motion based on the determined stage of the test cycle. 11. A method of in vitro analysis of a sample comprising blood cells, comprising: inserting a test device in a port of an analyzer comprising a computing device and at least one accelerometer; receiving the sample comprising the blood cells in a sample entry port of the test device actuating a pump, thereby moving the received sample in the test device through a conduit over at least one sensor configured to generate an electric signal based on: (i) a concentration of a target analyte in the sample, or (ii) a property of the sample, upon the at least one sensor being contacted with the sample in the conduit during a test cycle of the test device; determining spatial orientation and/or motion of the analyzer during the test cycle of the test device by the computing device using data collected by the at least one accelerometer; comparing at least one of: the determined spatial orientation to a threshold operating spatial plane for the test device, and the determined motion to a threshold rate of motion for the test device; and applying a correction factor to the electric signal generated by the at least one sensor, when at least one of: (i) the determined spatial orientation exceeds the threshold operating spatial plane, and (ii) the determined motion exceeds the threshold rate of motion, wherein the correction factor is at least one of a blood non-homogeneity correction factor, a blood cell sedimentation correction factor, and a blood motion factor; to produce a corrected signal. 12. The method of claim 11, wherein the blood cells from the sample at least partially sediment on the at least one sensor during the test cycle. 13. The method of claim 12, wherein a rate of cell sedimentation with respect to the at least one sensor is dependent on at least one of the spatial orientation and the motion of the analyzer during the test cycle. 14. The method of claim 11, wherein the at least one sensor is an electrochemical sensor. 15. The method of claim 11, wherein the at least one sensor responds to the target analyte or the property selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), beta human chorionic gonadotropin (bHCG), carbon dioxide partial pressure (pCO2), partial pressure oxygen (pO2), pH, prothrombin time (PT), activated clotting time (ACT), activated partial thromboplastin time (APTT), and prothrombin time international normalized ratio (PT INR), sodium, potassium, chloride, calcium, urea, glucose, creatinine, lactate, oxygen and carbon dioxide. 16. The method of claim 11, wherein the at least one sensor responds to the target analyte or the property selected from the group consisting of: hematocrit, troponin, creatine kinase myocardial band (CKMB), brain natriuretic peptide (BNP), activated clotting time (ACT), activated partial thromboplastin time (APTT) and prothrombin time international normalized ratio (PT INR). 17. The method of claim 11, wherein the computing device is configured to measure dynamic acceleration and/or static acceleration to determine the motion and/or the spatial orientation of the analyzer, respectively. 18. The method of claim 17, wherein the computing device is configured to measure static acceleration on at least three axes of the analyzer to determine the spatial orientation of the analyzer, and the determining the spatial orientation comprises determining at least one of roll, pitch, and yaw of the analyzer based on the measured static acceleration on the at least three axes of the analyzer. 19. The method of claim 11, wherein: the comparing the determined spatial orientation to the threshold operating spatial plane comprises at least one of: comparing the determined roll of the analyzer to a threshold roll; comparing the determined pitch of the analyzer to a threshold pitch; and comparing the determined yaw of the analyzer to a threshold yaw; and applying the correction factor when the determined spatial orientation exceeds the threshold operating spatial plane comprises applying the correction factor when at least one of: (iii) the determined roll of the analyzer exceeds the threshold roll, (iv) the determined pitch of the analyzer exceeds the threshold pitch, and (v) the determined yaw of the analyzer exceeds the threshold yaw, wherein the correction factor is at least one of the blood non-homogeneity correction factor and the blood cell sedimentation correction factor. 20. The method of claim 11, further comprising: determining a stage of the test cycle by the analyzer; and determining by the computing device at least one of the threshold operating spatial plane and the threshold rate of motion based on the determined stage of the test cycle.

Details for Patent 10,468,123

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2038-01-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2038-01-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2038-01-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2038-01-23
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2038-01-23
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2038-01-23